Table 3.

Univariate and multivariate analysis of the factors associated with RFS

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	$P$-value	HR (95% CI)	$P$-value
Age (year)	0.98 (0.98, 0.99)	0.002	0.99 (0.98–1.00)	0.011
Gender
Female	1
Male	1.25 (0.91, 1.70)	0.169	1.18 (0.86–1.62)	0.307
ALT (IU/L)	1.00 (1.00, 1.00)	0.986
AST (IU/L)	1.00 (1.00, 1.00)	0.514
TBIL($\mu$mol/L)	1.00 (0.98, 1.01)	0.358
PT (s)	1.05 (0.95, 1.17)	0.322
HBV-DNA
No	1
Yes	1.47 (1.16, 1.85)	0.001	1.21 (0.95–1.54)	0.118
Tumor diameter (cm)	1.12 (1.08, 1.15)	0.001	1.07 (1.04–1.11)	0.001
Tumor number
1	1
Multiple	1.62 (1.20, 2.19)	0.002	1.55 (1.14–2.11)	0.005
Differentiation
Low	1
Middle	0.71 (0.49, 1.03)	0.068
High	0.51 (0.31, 0.87)	0.012
PVTT
No	1
Yes	2.15 (1.53, 3.02)	0.001	1.07 (0.73–1.59)	0.722
MVI
No	1
Yes	2.22 (1.76, 2.81)	0.001	1.80 (1.40–2.31)	0.001
Paracancerous tissue infiltration
No	1
Yes	1.06 (0.75, 1.48)	0.753
Invasion of liver capsule
No	1
Yes	1.57 (1.22, 2.03)	0.001
Cirrhosis
No	1
Yes	1.04 (0.82, 1.33)	0.73	0.94 (0.73–1.21)	0.629
Child-Pugh
A	1
B	1.65 (1.12, 2.43)	0.011	1.09 (0.72–1.63)	0.687
BCLC
0–A	1
B	1.84 (1.12, 3.03)	0.015
C	1.13 (0.88, 1.44)	0.345
D	0.60 (0.15, 2.43)	0.473
AAPR group
$⩽$ 0.52	1
$>$ 0.52	0.58 (0.45, 0.75)	0.001	0.70 (0.53–0.92)	0.011

RFS: recurrence-free survival; HR: Hazard ratio; AAPR: albumin-alkaline phosphatase ratio; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; HGB: hemoglobin; PT: prothrombin time; HBV: hepatitis B virus; PVTT: portal vein tumor thrombus; MVI: microvascular infiltration; BCLC: Barcelona Clinic Liver Cancer.